Compare · JANX vs NVO
JANX vs NVO
Side-by-side comparison of Janux Therapeutics Inc. (JANX) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both JANX and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $215.46B, about 188.7x JANX ($1.14B).
- NVO has been more active in the news (9 items in the past 4 weeks vs 5 for JANX).
- NVO has more recent analyst coverage (25 ratings vs 20 for JANX).
- Company
- Janux Therapeutics Inc.
- Novo Nordisk A/S
- Price
- -
- -
- Market cap
- $1.14B
- $215.46B
- 1M return
- -
- -2.08%
- 1Y return
- -
- -12.07%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2021
- News (4w)
- 5
- 9
- Recent ratings
- 20
- 25
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest JANX
- Janux Therapeutics upgraded by Wolfe Research with a new price target
- Amendment: SEC Form SCHEDULE 13G/A filed by Janux Therapeutics Inc.
- SEC Form 10-Q filed by Janux Therapeutics Inc.
- Janux Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Janux Therapeutics Reports Second Quarter 2026 Financial Results and Business Highlights
- President and CEO Campbell David Alan gifted 123,840 shares, decreasing direct ownership by 32% to 264,742 units (SEC Form 4)
- President and CEO Campbell David Alan exercised 7,000 shares at a strike of $4.21, increasing direct ownership by 2% to 388,582 units (SEC Form 4)
- Janux Therapeutics Inc. filed SEC Form 8-K: Other Events
- Director Ra Capital Management, L.P. was granted 5,500 shares (SEC Form 4)
- Director Simson Jake was granted 5,500 shares (SEC Form 4)
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- A New Category Is Forming in Medical Aesthetics. Independent Research Has Started Sizing It.
- SEC Form 6-K filed by Novo Nordisk A/S
- Novo Nordisk A/S downgraded by Berenberg
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S